BridgeBio Pharma
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 556
- Market Cap
- $4.6B
- Website
- http://www.bridgebio.com
- Introduction
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Benuvia Operations Secures ANVISA GMP Certification, Expanding Pharmaceutical Manufacturing Capabilities in Brazil
Benuvia Operations has received Good Manufacturing Practices certification from Brazil's National Health Surveillance Agency (ANVISA), enabling the company to manufacture and distribute pharmaceutical products in Latin America's largest healthcare market.
Merck KGaA in Advanced Talks to Acquire SpringWorks Therapeutics; BridgeBio Secures EU Approval for ATTR Drug
Merck KGaA confirms advanced acquisition discussions with SpringWorks Therapeutics, though critical conditions remain unmet and no binding agreement has been reached.
BridgeBio's Attruby Approved for ATTR-CM, Cassava's Simufilam Fails in Alzheimer's Trial
BridgeBio Pharma's Attruby (acoramidis) receives FDA approval for transthyretin amyloidosis cardiomyopathy (ATTR-CM), reducing cardiovascular death and hospitalization.
FDA Approves BridgeBio's Attruby (acoramidis) for ATTR-CM
The FDA has approved Attruby (acoramidis) by BridgeBio Pharma for treating transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, marking a significant advancement in cardiac care.
FDA Approves BridgeBio's Attruby (acoramidis) for Transthyretin Amyloid Cardiomyopathy
The FDA has approved BridgeBio Pharma's Attruby (acoramidis) for treating transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, marking a significant advancement in cardiac care.
FDA Approves BridgeBio's Attruby (acoramidis) for ATTR-CM Treatment
The FDA has approved BridgeBio Pharma's Attruby (acoramidis) for treating transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, marking a significant advancement in cardiac care.
FDA Approves BridgeBio's Acoramidis (ATTRUBY) for Transthyretin Amyloid Cardiomyopathy
The FDA has approved acoramidis (ATTRUBY), an oral transthyretin stabilizer, for treating transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, aiming to reduce cardiovascular death and hospitalization.
FDA Approves BridgeBio's Attruby for Transthyretin Amyloid Cardiomyopathy
The FDA has approved BridgeBio's Attruby (acoramidis) for transthyretin amyloid cardiomyopathy, offering a new treatment option.
FDA Approves Acoramidis (ATTRuby) for Transthyretin Amyloid Cardiomyopathy
The FDA has approved acoramidis (ATTRuby) by BridgeBio Pharma for treating transthyretin amyloid cardiomyopathy (ATTR-CM), offering a new treatment option.
FDA Approves Attruby (Acoramidis) for ATTR-CM, Reducing Cardiovascular Death and Hospitalization
The FDA has approved Attruby (acoramidis) for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), addressing both wild-type and variant forms of the disease.